http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020040055-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a92803f6cf472da3edb056e6ddcf5fb5
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
filingDate 2017-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00f49811404372ce545a539a8025b336
publicationDate 2020-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2020040055-A1
titleOfInvention Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
abstract The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HLA-A2 complex fused to a CD3 binding T cell redirecting moiety.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023099622-A1
priorityDate 2016-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5394
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66767268
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66767269
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398738
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397199
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5754
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395857
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396196
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226975279
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226975280

Total number of triples: 49.